Supriya Lifescience is currently trading at Rs. 734.45, up by 17.65 points or 2.46% from its previous closing of Rs. 716.80 on the BSE.
The scrip opened at Rs. 726.00 and has touched a high and low of Rs. 736.10 and Rs. 717.25 respectively. So far 4718 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 835.35 on 04-Dec-2024 and a 52 week low of Rs. 269.90 on 20-Dec-2023.
Last one week high and low of the scrip stood at Rs. 775.30 and Rs. 715.00 respectively. The current market cap of the company is Rs. 5947.28 crore.
The promoters holding in the company stood at 68.30%, while Institutions and Non-Institutions held 11.48% and 20.23% respectively.
Supriya Lifescience (SLL) has inaugurated its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site. The facility, developed with an investment of approximately Rs 125 crore, adds a substantial capacity of 335 kiloliters to the company’s operations. This expansion boosts Lote Parshuram capacity by over 55%, increasing it from 597 KLPD to 932 KLPD.
The new production block is designed to support SLL’s strategic focus on expanding its R&D capabilities and scaling up its pipeline of innovative products. Several new products in niche therapeutic areas are nearing the commercialization stage, reinforcing SLL’s commitment to achieving a leadership position in these markets through efficient processes and backward integration.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1802.50 |
Dr. Reddys Lab | 1277.15 |
Cipla | 1478.90 |
Lupin | 2100.45 |
Zydus Lifesciences | 983.25 |
View more.. |